o NoneEntity Type
0001053691
RestorGenex Corp
Stratus Media Group, Inc
FERIS INTERNATIONAL, INC.
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
 Diffusion Pharmaceuticals Inc.
Jurisdiction of Incorporation/OrganizationDELAWARE 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed 



2. Principal Place of Business and Contact Information
Name of Issuer 
 Diffusion Pharmaceuticals Inc. 
Street Address 1Street Address 2
 1317 CARLTON AVENUE SUITE 200
CityState/Province/CountryZIP/Postal CodePhone No. of Issuer
 CHARLOTTESVILLE VIRGINIA 22902 (434) 220-0718 



3. Related Persons
Last NameFirst NameMiddle Name
KalergisDavidG.
Street Address 1Street Address 2
1317 Carlton AvenueSuite 200
CityState/Province/CountryZIP/Postal Code
CharlottesvilleVIRGINIA22902
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
GainerJohnL.
Street Address 1Street Address 2
1317 Carlton AvenueSuite 200
CityState/Province/CountryZIP/Postal Code
CharlottesvilleVIRGINIA22902
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
AdamsRobertW.
Street Address 1Street Address 2
1317 Carlton AvenueSuite 200
CityState/Province/CountryZIP/Postal Code
CharlottesvilleVIRGINIA22902
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
HornungWilliamK.
Street Address 1Street Address 2
1317 Carlton Avenue
CityState/Province/CountryZIP/Postal Code
CharlottesvilleVIRGINIA22902
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

 
Last NameFirst NameMiddle Name
ByrneThomasS.
Street Address 1Street Address 2
1317 Carlton AvenueSuite 200
CityState/Province/CountryZIP/Postal Code
CharlottesvilleVIRGINIA22902
Relationship: x Executive Officer o Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
GilesMarkT.
Street Address 1Street Address 2
1317 Carlton AvenueSuite 200
CityState/Province/CountryZIP/Postal Code
CharlottesvilleVIRGINIA22902
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
LevinAlanG.
Street Address 1Street Address 2
1317 Carlton AvenueSuite 200
CityState/Province/CountryZIP/Postal Code
CharlottesvilleVIRGINIA22902
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

Last NameFirst NameMiddle Name
CobuzziRobertJ.
Street Address 1Street Address 2
1317 Carlton AvenueSuite 200
CityState/Province/CountryZIP/Postal Code
CharlottesvilleVIRGINIA22902
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
  

 


4. Industry Group
o Agriculture Health Care o Retailing
 Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance Technology
  o Insurance  o Hospitals & Physicians  o Computers
  o Investing  x Pharmaceuticals  o Telecommunications
  o Investment Banking  o Other Health Care  o Other Technology
  o Pooled Investment Fund

    Travel
  o Other Banking & Financial Services o Manufacturing  o Airlines & Airports
 Real Estate  o Lodging & Conventions
  o Commercial  o Tourism & Travel Services
  o Construction  o Other Travel
  o REITS & Finance o Other
  o Residential 
  o Other Real Estate 
o Business Services 
 Energy 
  o Coal Mining 
  o Electric Utilities 
  o Energy Conservation 
  o Environmental Services 
  o Oil & Gas 
  o Other Energy 


5. Issuer Size
Revenue RangeAggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale 2020-05-08 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities o Debt
o Mineral Property Securities x Option, Warrant or Other Right to Acquire Another Security
x Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
  


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary) 
  

11. Minimum Investment
Minimum investment accepted from any outside investor$ 0 USD

12. Sales Compensation
RecipientRecipient CRD Number o None
 H.C. Wainwright & Co., LLC 375
(Associated) Broker or Dealer x None(Associated) Broker or Dealer CRD Number x None
    
Street Address 1Street Address 2
 430 Park Avenue 4th Floor
City State/Province/CountryZIP/Postal Code
 New York NEW YORK 10022
State(s) of Solicitation x All States x Foreign/Non-US
 

 



13. Offering and Sales Amounts
Total Offering Amount $ 625000 USD o Indefinite
Total Amount Sold $ 625000 USD 
Total Remaining to be Sold $ 0 USD o Indefinite
 
Clarification of Response (if Necessary)
  


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 1


15. Sales Commissions & Finders’ Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions$ 100000 USD x Estimate
Finders' Fees$ 0 USD o Estimate
 
Clarification of Response (if Necessary)
 H.C. Wainwright & Co., LLC also received warrants to purchase up to 250,000 shares of common stock.


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
 $ 0 USD o
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Diffusion Pharmaceuticals Charts.
Diffusion Pharmaceuticals (NASDAQ:DFFN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Diffusion Pharmaceuticals Charts.
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No DFFN Message Board. Create One! See More Posts on DFFN Message Board See More Message Board Posts

Diffusion Pharmaceuticals Inc. News

Loading Messages....

More Diffusion Pharmaceuticals Inc. News Articles